Analytik Jena with Good Results in the First Half of the Financial Year 2011/2012

• Revenue growth in the second quarter offsets weaker first quarter
• Growth in Asia well into double digits at 23.4 %
• Earnings with double-digit growth rates

Jena, May 10, 2012 — After six months of the current financial year, Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) has recorded very good development of its operating business. The instrument manufacturer for analytical measuring technology and life science generated consolidated revenue of EUR 46.0 m (previous year: EUR 44.5 m). With growth rates of 26.3 % in operating profit (EBIT), 156.2 % in earnings before tax, 156.3 % in consolidated net profit for the period and 161.5 % in earnings per share, the company considerably improved its earnings situation after six months compared with the previous year.

“We succeeded in compensating for the somewhat weaker start to the new financial year and have achieved significant progress year-on-year on the revenue and income side. We have thus created a good base from which we can realize our goals for the financial year as a whole,” said Klaus Berka, CEO of Analytik Jena AG.

Revenue Development and Segments

After the first quarter of the current financial year remained below the previous year, operational business benefited from very good business in the second quarter. As a result, Analytik Jena was able to achieve growth totaling 3.5 % after six months.

Revenue in the Asia region, by far the most important region for the Company, rose considerably once again. In this region, a double-digit gain of 23.4 % was generated after six months, with revenue of EUR 17.5 m (previous year: EUR 14.2 m). For the first time, business in Asia benefited particularly from the development in Japan. In the course of the second quarter, Analytik Jena’s business development accelerated markedly in this market, following the portfolio expansion with x-ray fluorescence devices as part of a distribution partnership with the Japanese company Techno-X.

After the first six months of the current financial year, Analytik Jena also draws an overall positive conclusion in respect to revenue of the three segments. Revenue in the core business Analytical Instrumentation was 6.3 % higher year-on-year at EUR 29.5 m (previous year: EUR 27.7 m). The Life Science business unit achieved revenue of EUR 13.9 m (previous year: EUR 14.3 m) and was down on the previous year’s figures by 2.9 %. This is mainly due to slightly declining revenue at CyBio AG, which is consolidated in this unit. In the smallest business unit, Optics, Analytik Jena generated revenue of EUR 2.6 m (previous year: EUR 2.4 m) in the reporting period, exceeding the previous-year figure by 9.4 %.

Result

Analytik Jena increased its results significantly in the reporting period. The Group generated earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 5.3 m (previous year: EUR 4.5 m), up 18.7 % on the previous year. Operating profit (EBIT) also was up by 26.3 % and amounted to EUR 3.3 m (previous year: EUR 2.6 m) with an EBIT margin of 7.2 % (previous year: 5.9 %). Earnings before tax (EBT) of EUR 2.9 m (previous year: EUR 1.1 m), which more than doubled year-on-year, benefited especially from a positive result from the investment of the 49 % minority interest investment AJZ Engineering and from favorable foreign exchange rate movements in the financial year so far. Overall, the Group posted net profit for the period of EUR 2.0 m (previous year: EUR 0.8 m), which corresponds to an increase of 156.3 %. The share of this attributable to the shareholders of Analytik Jena AG totals EUR 1.8 m (previous year: EUR 0.7 m), which corresponds to earnings per share of EUR 0.34 (previous year: EUR 0.13).

Changes in Statement of Financial Position

The Group’s total assets as of the balance sheet date on March 31, 2012 increased from EUR 83.6 m to EUR 89.1 m. In the reporting period, Analytik Jena showed equity of EUR 45.3 m (as of September 30, 2011: EUR 38.6 m). This corresponds to an increase of 17.5 %, which, in addition to the results contribution, mainly results from the capital increase carried out at the beginning of 2012. The equity ratio rose from 46.1 % as of September 30, 2011 to 50.8 % as of March 31, 2012. On the assets side, cash and cash equivalents increased in the same context by 73.3 % in comparison with the end of the 2010/2011 financial year and amounted to EUR 9.5 m as of the balance sheet date (as of September 30, 2011: EUR 5.5 m). The capital increase of EUR 4.9 m carried out at the beginning of February, which together with external financing was intended in particular for retroactive tax payments, the offer to CyBio AG shareholders in connection with the planned delisting and a strategic expansion of the portfolio, the realization of which failed in retrospect directly before the contract was signed, stabilized the Company’s liquidity position and improved the equity base. In the reporting period, Analytik Jena recorded operating cashflow of EUR 1.5 m.

Human Resources

As of the balance sheet date of March 31, 2012, the Group employed 813 staff, including 37 trainees (previous year: 800 employees, including 39 trainees).

Outlook

Based on the good first half of 2011/2012, Analytik Jena expects the positive development of its business to continue over the year as a whole. The Company anticipates that all three segments will contribute to revenue and earnings growth. In line with its forecast for the year, Analytik Jena AG estimates the expected consolidated revenue for the financial year 2011/2012 at between EUR 91.0 m and EUR 93.0 m as well as expected operating profit at more than EUR 6.0 m.

Further Information

The full financial report is available at http://berichte.analytik-jena.de/6-MonthReport_1112.pdf.